Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.44 |
| ▸ | LMNA | P02545 | 3/20 | 0.44 |
| ▸ | POLB | P06746 | 3/20 | 0.44 |
| ▸ | CASP6 | P55212 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.41 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.40 |
| ▸ | NCF1 | P14598 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 4/20 | 0.38 |
| ▸ | GAA | P10253 | 3/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.38 |
| ▸ | HPGD | P15428 | 3/20 | 0.38 |
| ▸ | CASP1 | P29466 | 3/20 | 0.38 |
| ▸ | CASP7 | P55210 | 3/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.38 |
| ▸ | GLA | P06280 | 2/20 | 0.38 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.38 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.38 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.38 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2847830 | 0.90 | NR4A2 (0.41) | KDM4ELMNAPOLBCASP6ALDH1A1 | |
| SCHEMBL9248212 | 0.80 | ALDH1A1 (0.43) | KDM4ELMNAPOLBCASP6ALDH1A1 | |
| SCHEMBL7455519 | 0.80 | KDM4E (0.47) | KDM4ELMNAPOLBCASP6ALDH1A1 | |
| SCHEMBL4058945 | 0.80 | ALDH1A1 (0.43) | KDM4ELMNAPOLBCASP6ALDH1A1 | |
| SCHEMBL564343 | 0.80 | ALDH1A1 (0.51) | KDM4ELMNAPOLBCASP6ALDH1A1 | |
| SCHEMBL24936489 | 0.77 | KDM4E (0.48) | KDM4ELMNAPOLBCASP6ALDH1A1 | |
| SCHEMBL564769 | 0.77 | LMNA (0.46) | KDM4ELMNAPOLBCASP6ALDH1A1 | |
| SCHEMBL5215349 | 0.77 | ALDH1A1 (0.41) | KDM4ELMNAPOLBCASP6ALDH1A1 | |
| SCHEMBL31556360 | 0.77 | ALDH1A1 (0.41) | KDM4ELMNAPOLBCASP6ALDH1A1 | |
| SCHEMBL2884751 | 0.77 | ALDH1A1 (0.41) | KDM4ELMNAPOLBCASP6ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140200354-A1 | Process for the Manufacture of Non-Steroidal Anti-Inflammatory Agents and Intermediates Thereof | INTENDIS GMBH (DE) | 2014-07-17 | — | — | US | claimed |
| US-20120035371-A1 | PROCESS FOR THE MANUFACTURE OF NON-STEROIDAL ANTI-INFLAMMATORY AGENTS AND INTERMEDIATES THEREOF | SCHWEIZER STEFFEN (DE) | 2012-02-09 | — | — | US | claimed |
| US-8071796-B2 | Process for the manufacture of non-steroidal anti-inflammatory agents and intermediates thereof | INTENDIS GMBH (DE) | 2011-12-06 | — | — | US | claimed |
| US-20080274517-A1 | PROCESS FOR THE MANUFACTURE OF NON-STEROIDAL ANTI-INFLAMMATORY AGENTS AND INTERMEDIATES THEREOF | INTENDIS GMBH (DE) | 2008-11-06 | — | — | US | claimed |
| EP-1982976-A1 | Process for the manufacture of non-steroidal anti-inflammatory agents and intermediates thereof | Intendis GmbH (DE) | 2008-10-22 | — | — | EP | claimed |
| US-20240016795-A1 | BROMODOMAIN INHIBITORS FOR ANDROGEN RECEPTOR-DRIVEN CANCERS | FORMA THERAPEUTICS INC (US) | 2024-01-18 | — | — | US | disclosed |
| US-20240016795-A1 | BROMODOMAIN INHIBITORS FOR ANDROGEN RECEPTOR-DRIVEN CANCERS | FORMA THERAPEUTICS INC (US) | 2024-01-18 | — | — | US | disclosed |
| US-11801243-B2 | Bromodomain inhibitors for androgen receptor-driven cancers | FORMA THERAPEUTICS, INC. (US) | 2023-10-31 | — | — | US | disclosed |
| US-11801243-B2 | Bromodomain inhibitors for androgen receptor-driven cancers | FORMA THERAPEUTICS, INC. (US) | 2023-10-31 | — | — | US | disclosed |
| US-20140200354-A1 | Process for the Manufacture of Non-Steroidal Anti-Inflammatory Agents and Intermediates Thereof | INTENDIS GMBH (DE) | 2014-07-17 | — | — | US | disclosed |
| US-20120035371-A1 | PROCESS FOR THE MANUFACTURE OF NON-STEROIDAL ANTI-INFLAMMATORY AGENTS AND INTERMEDIATES THEREOF | SCHWEIZER STEFFEN (DE) | 2012-02-09 | — | — | US | disclosed |
| US-8071796-B2 | Process for the manufacture of non-steroidal anti-inflammatory agents and intermediates thereof | INTENDIS GMBH (DE) | 2011-12-06 | — | — | US | disclosed |
| WO-2006050998-A1 | 5-SUBSTITUTED QUINOLINE AND ISOQUINOLINE DERIVATIVES, A METHOD FOR THE PRODUCTION THEREOF AND THEIR USE AS ANTIPHLOGISTICS | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2006-05-18 | — | — | WO | disclosed |
| US-5656634-A | N-aryl and N-heteroarylamide and urea derivatives as inhibitors of acyl coenzyme A: cholesterol acyl transferase (ACAT) | PFIZER INC. (US) | 1997-08-12 | — | — | US | disclosed |
| US-5362878-A | Intermediates for making N-aryl and N-heteroarylamide and urea derivatives as inhibitors of acyl coenzyme A: cholesterol acyl transferase (ACAT) | PFIZER INC. (US) | 1994-11-08 | — | — | US | disclosed |
| WO-1991004027-A1 | NEW N-ARYL AND N-HETEROARYLAMIDE AND UREA DERIVATIVES AS INHIBITORS OF ACYL COENZYME A: CHOLESTEROL ACYL TRANSFERASE (ACAT) | PFIZER INC. (US) | 1991-04-04 | — | — | WO | disclosed |
| EP-0418071-A2 | New N-aryl and N-heteroarylamide and urea derivatives as inhibitors of acyl coenzyme A: cholesterol acyl transferase | PFIZER INC. (US) | 1991-03-20 | — | — | EP | disclosed |
| US-4567269-A | BACTERICIDES | RIKER LABORATORIES, INC. (US) | 1986-01-28 | — | — | US | disclosed |
| US-4472406-A | Antimicrobial 6,7-dihydro-8-(imidazol-1-yl)-5-methyl-1-oxo-1H,5H-benzo [ij]quinolizine-2-carboxylic acids and derivatives | RIKER LABORATORIES, INC. (US) | 1984-09-18 | — | — | US | disclosed |
| EP-0109285-A1 | 6,7-Dihydro-8-(imidazol-1-yl)-5-methyl-1-oxo-1H,5H-benzo(ij)quinolizine-2-carboxylic acids and derivatives | RIKER LABORATORIES, INC. (US) | 1984-05-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080274517-A1 | PROCESS FOR THE MANUFACTURE OF NON-STEROIDAL ANTI-INFLAMMATORY AGENTS AND INTERMEDIATES THEREOF | CYP2F1, CYP4A11, CYP11B1 | KDM4E 1779/4885LMNA 3079/4885POLB 3041/4885 |
| US-20120035371-A1 | PROCESS FOR THE MANUFACTURE OF NON-STEROIDAL ANTI-INFLAMMATORY AGENTS AND INTERMEDIATES THEREOF | CYP2F1, CYP4A11, CYP11B1 | KDM4E 1779/4885LMNA 3079/4885POLB 3041/4885 |
| US-20240016795-A1 | BROMODOMAIN INHIBITORS FOR ANDROGEN RECEPTOR-DRIVEN CANCERS | BRDT, AR, BRD4 | KDM4E 401/4885LMNA 3589/4885POLB 2188/4885 |
| US-11801243-B2 | Bromodomain inhibitors for androgen receptor-driven cancers | BRDT, AR, BRD4 | KDM4E 401/4885LMNA 3589/4885POLB 2188/4885 |
| US-20140200354-A1 | Process for the Manufacture of Non-Steroidal Anti-Inflammatory Agents and Intermediates Thereof | CYP2F1, CYP4A11, CYP11B1 | KDM4E 1742/4885LMNA 3066/4885POLB 3071/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.